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ABSTRACT
Heart failure with preserved ejection fraction (HFpEF) has recently been recognized as 
the single greatest unmet need in cardiovascular medicine. As the population ages and 
the comorbidity increases, the prevalence of HFpEF increases considerably. Even though 
there have been large numbers of studies on pathophysiology, diagnosis, and treatment of 
HFpEF for latest years, there are no current pharmacologic interventions that can reduce 
mortality. HFpEF is currently understood as a heterogeneous syndrome originated from the 
interplay of cardiac and extracardiac abnormalities recognized by systemic inflammation, 
endothelial and coronary microvascular dysfunction, cardiomyocyte dysfunction and skeletal 
muscle dysfunction. The difficult “jigsaw puzzle” called HFpEF has been filled with some 
pieces, but it is still not enough to meet clinical needs. Here, we review recent evidences and 
unsolved problems about HFpEF to improve our understanding of HFpEF. Finally, we hope to 
accelerate to completion of the problematic “jigsaw puzzle”.
Keywords: Heart failure with preserved ejection fraction; Syndrome; Pathophysiology; 
Diagnosis; Treatment
INTRODUCTION
Approximately half of patients with signs and symptoms of heart failure (HF) have preserved 
ejection fraction.1-6) As the population ages and the comorbidity increases, the prevalence 
of HF with preserved ejection fraction (HFpEF) increases considerably.1)3-6) The results of 
the early epidemiologic study revealed that patients with HFpEF were older, more female, 
and had a higher rate of comorbidity, such as hypertension, diabetes mellitus (DM), 
obesity, chronic kidney disease, and atrial fibrillation (AF).1) What these patients have in 
common is that ejection fraction is preserved, but there are symptoms and signs of clinical 
HF. Therefore, it has been considered a kind of syndrome in the absence of a confirmative 
diagnostic or therapeutic indicator. The basic question is whether we have to continue to 
fill this difficult “jigsaw puzzle” named HFpEF, or whether we have to make a new base after 
breaking all of the HF classification methods based on ejection traction. In this review, we 
will review some pretty meaningful pieces that are already set in the puzzle, and we believe 
that these will not be changed even if the base of the puzzle changes.
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HEART FAILURE WITH PRESERVED EJECTION FRACTION 
VS. DIASTOLIC HEART FAILURE
HFpEF was initially termed diastolic HF.7) HFpEF and diastolic HF have been used 
interchangeably and confusedly for the last 20 years. In principle, HFpEF and diastolic HF 
are not the same diagnostic terms, and the former should be understood to a larger range 
of diagnosis since several alternative and complementary mechanisms exist either presence 
or absence of left ventricular (LV) diastolic dysfunction (Figure 1).8)9) There has been a recent 
expansion of the ejection fraction derived classification of patients with HF. Accordingly, 
HF with midrange ejection fraction and HF with improved ejection fraction appeared 
recently.10)11) Therefore, the term “diastolic HF” tends not to be used although diastolic HF 
is also an important term in terms of mechanism. Each of these two terms has its pros and 
cons. For example, if a patient presented with HF but a meaningful diastolic dysfunction 
or elevation of LV filling pressure are not proven in diagnostic tests, the patients can be 
diagnosed with HFpEF, but not enough to be diagnosed with diastolic HF. In the case of 
HFpEF which the diastolic dysfunction is not proven, there is a fundamental limitation in 
developing a therapeutic agent because of lack of any indicators to monitor. In order to 
overcome these shortcomings of HFpEF, there is a trend to classify several key phenotypes 
in this heterogeneous disease, and construct a treatment strategy according to the main 
pathophysiology.
PATHOPHYSIOLOGY AND PHENOTYPES OF HEART 
FAILURE WITH PRESERVED EJECTION FRACTION
There have been a number of efforts to defining phenotypes of patients with HFpEF according 
to their main features and pathophysiology after a few clinical trials, but repetitively failed to 
prove benefits of potential pharmacologic treatments in this heterogeneous syndrome.12-15) 
Different treatment strategies according to the phenotype have been presented very 
convincingly, however, it is often difficult to specify this as only one phenotype.12-15)
Representative phenotypic classifications of HFpEF are presented in Figures 2 and 3, which 
might help physicians to understand the main clinical presentation and pathophysiology 
in managing patients with HFpEF.12)15) As shown in Figure 2, patients with HFpEF can be 
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Longitudinal LV systolic dysfunction
Abnormal ventricular-vascular coupling
Abnormal exercise induced vasodilation
Chronotropic incompetence
Pulmonary hypertension
Figure 1. Basic concepts of diastolic HF and HFpEF. 
HF = heart failure; HFpEF = heart failure with preserved ejection fraction; LV = left ventricular.
roughly classified into 3 phenotypes: exercise induced elevation of LV filling pressures, 
volume overload or right HF.12) The first phenotype of “exercise-induced elevation of LV 
filling pressures”, expressing the lowest risk type, but also the most difficult to diagnose as 
HFpEF.12) The predominant symptom in these patients is exertional dyspnea and there are no 
definite clues in echocardiographic features or brain natriuretic peptide (BNP) levels.12) The 
second phenotype of “volume overload” is the common one that physicians recognize.12) The 
third phenotype of “right HF” is the highest risk clinical subclass with poor prognosis.12) An 
another attractive phenotype classification of HFpEF that provides clinicians with a specific 
and effective therapeutic strategies to individual patients is demonstrated in Figure 3.15) 
There are 8 phenotypes, which include predominant metabolic syndrome (often referred to 
as “garden variety” associated with hypertension, obesity, DM, metabolic syndrome, and/
or chronic kidney disease), coronary artery disease, predominant right HF, AF, hypertrophic 
cardiomyopathy like phenotype, valvular heart disease, high-output HF, rare causes such 
as restrictive cardiomyopathy or constrictive pericarditis.15) This phenotype classification 
based on etiology and pathophysiology is quite helpful in guiding initial treatment, but not 
mutually exclusive, and therefore sometimes difficult to place patients into a single category.15) 
However, even in patients classified as a garden variety phenotype after exclusion of certain 
diseases that require specific treatment, the mechanism of HFpEF varies with a more 
predominant contributing components among aortic stiffness (increased afterload), cardio-
metabolic (systemic inflammation), and cardio-renal (increased preload) aspects. Recently, 
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Figure 2. Phenotype classification of HF with preserved ejection fraction based on clinical presentations. 
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; BNP = brain natriuretic peptide;  
BP = blood pressure; HF = heart failure; LV = left ventricular; PH = pulmonary hypertension; SGLT-2 = sodium-
glucose cotransporter-2.
a few novel “phenomapping” techniques by machine learning to define clusters of patients 
based on dense phenotypic data have been suggested to provide an unbiased way to classify 
heterogeneous clinical syndromes of HFpEF.16)17)
DIAGNOSTIC CHALLENGES IN HEART FAILURE WITH 
PRESERVED EJECTION FRACTION
The diagnosis of HFpEF is still challenging, because symptoms are nonspecific and can 
be explained by several alternative non-cardiac conditions, such as chronic lung disease, 
anemia, and chronic kidney disease.8) In patients with phenotypes of volume overload or 
right HF based on clinical presentation,12) it is not difficult to document typical signs and 
symptoms of HF, such as pulmonary congestion, elevated BNP, and advanced diastolic 
dysfunction on Doppler echocardiography. However, in patients with the phenotype of 
exercise-induced elevation of LV filling pressure especially in those with significant LV 
structural abnormalities, we often encounter a few problems of echocardiogram only 
assessed at rest for HFpEF diagnosis.18-20) First, diastolic dysfunction as assessed by 
echocardiogram is highly prevalent in the elderly population.19)20) Second, echocardiographic 
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Figure 3. Phenotype classification of HFpEF based on etiology and pathophysiology. 
AF = atrial fibrillation; CAD = coronary artery disease; HCM = hypertrophic cardiomyopathy; HF = heart 
failure; HFpEF = heart failure with preserved ejection fraction; PAH = pulmonary arterial hypertension; PDE5 = 
phosphodiesterase type 5.
variables indicating diastolic dysfunction may be absent in a significant proportion of 
patients diagnosed with HFpEF.19) The existing tools to assess LV systolic performance are 
far from perfect.19) Last, viewing HFpEF as results of ventricular stiffening and diastolic 
dysfunction only is an oversimplification although there are complementary and complex 
mechanisms.19) Additionally, exertional dyspnea is a common clinical problem. It can be 
complex and multiple etiologies such as respiratory causes, cardiac causes, metabolic 
causes and psychological causes.20) The differential diagnosis of HFpEF is challenging in 
stable elderly patients with equivocal symptoms. Therefore, we need to perform an exercise 
stress test because we cannot explain the patients' symptom completely with a resting 
echocardiography.20)21) A noninvasive diagnostic test for diastolic dysfunction using supine 
bicycle exercise Doppler echocardiography has been set up about 15 years ago.20) Because 
this echocardiographic method has advantages for evaluation of diastolic function during 
exercise. It is possible to get continuous imaging at each stages of exercise.20) Moreover, since 
the supine position increases myocardial wall tension and oxygen demand, it is suitable 
for diastolic stress.20) Currently, diastolic stress test is recommended for evaluation of 
exercise-induced elevation of LV filling pressure if the resting echocardiographic evaluation 
is inconclusive for diagnosis or exclusion of HFpEF.18)21) In a simultaneous invasive-echo 
study in patients with HFpEF and non-cardiac dyspnea, much improved diagnostic 
performance of adding exercise E/e′ on the European Society of Cardiology criteria were 
proven by demonstrating a 30% increase of sensitivity from 60% to 90%.18) In addition to 
the improvement of diagnostic performance and risk stratification of HFpEF,21-25) diastolic 
stress test can provide a prognostic information.26-28) Holland et al. showed the incremental 
prognostic implications of LV filling pressure with exercise in patients with or without 
inducible myocardial ischemia.26) Our previous work also demonstrated the prognostic 
values of exercise-induced elevation of LV filling pressure and consequent exercise-induced 
pulmonary hypertension in subjects with preserved LV ejection fraction (Figure 4).27) The 
types and methods of diastolic stress test vary from invasive to noninvasive techniques.21) 
Therefore, it is needed to apply an appropriate stress test after considering the patient's 
clinical situation and the established facility in each institution.
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No exercise-induced PH
Figure 4. Exercise-induced elevation of left ventricular filling pressure and exercise-induced PH detected by diastolic stress echocardiography. 
PASP = pulmonary artery systolic pressure; PH = pulmonary hypertension; TR = tricuspid regurgitation.
COMMON COMORBIDITIES IN HEART FAILURE WITH 
PRESERVED EJECTION FRACTION: HYPERTENSION AND 
ARTERIAL STIFFNESS
Arterial stiffness is a cardinal feature of vascular aging and hypertension.29) The aorta 
deliveries blood from the LV to the capillaries, acting as a highly efficient conduit and 
cushion. As the aorta stiffens, blood travels faster, returns earlier, and boosts pressure 
in late systole. As a result, arterial stiffness results in elevation of augmentation pressure 
and augmentation index, and widening of the arterial pulse pressure.30)31) Figure 5 shows 
the possible relationship between arterial stiffness and LV diastolic/longitudinal systolic 
dysfunction which was originally proposed by Mottram et al.32) Increased central systolic 
blood pressure (BP) results in increasing LV afterload and makes myocyte hypertrophy and 
impaired relaxation. Simultaneously, central aortic diastolic BP decreases.32) It reduces 
coronary perfusion and induces subendocardial ischemia and fibrosis.32) These adverse 
effects finally lead to LV diastolic dysfunction and longitudinal systolic dysfunction. Recent 
studies have demonstrated that noninvasively assessed central BP and variables reflecting 
arterial mechanical function at rest and with exercise are well correlated with LV diastolic 
function and LV systolic functional impairments such as LV global longitudinal strain and 
apical rotation.33-38) In terms of sex difference in HFpEF, the indices reflecting central arterial 
stiffness in radial arterial tonometry were higher in women than in men.38) Additionally, we 
found that the relationship between variables of arterial stiffness and LV diastolic function 
was stronger in women.38) In another study, the dynamic changes of arterial elastance during 
exercise in patients with hypertension were investigated.39) When age-matched men and 
women with hypertension were compared, there was a steeper rise of arterial elastance index 
during exercise in hypertensive women.39) Moreover, the arterial elastance index during 
exercise was an independent determinant of exercise duration.39) To summarize, arterial 
stiffness and ventricular-vascular interaction at rest and dynamic changes during stress are 
considered a principal pathophysiology in patients with HFpEF and should be a therapeutic 
target for preventing HFpEF.40-43)
1056https://e-kcj.org https://doi.org/10.4070/kcj.2020.0338
Heart Failure with Preserved Ejection Fraction
Aortic stiffness











Figure 5. Pathophysiologic relationship between arterial stiffness and LV dysfunction. 
DBP = diastolic blood pressure; LV = left ventricular; SBP = systolic blood pressure.
DIABETES MELLITUS
DM is a common comorbidity in HF and has an adverse impact on prognosis.44)45) Classically, 
many studies have been conducted on the mechanisms and treatment strategies of diabetic 
cardiomyopathy, in which myocardial dysfunction occurs in absence of significant coronary 
artery stenosis in patients with DM.46)47) Although definite pathophysiological mechanisms 
of DM in HFpEF have yet to be elucidated, several common pathological mechanisms 
have been suggested including microvascular dysfunction, metabolic derangements and 
systemic inflammation, sodium retention, and impaired skeletal muscle function.45) Insulin 
resistance in DM leads to increase free fatty acid utilization by cardiac myocytes, which may 
lead to mitochondrial dysfunction, production of toxic lipid intermediates, and increased 
reactive oxygen species.45) Hyperglycemia-induced advanced glycation end products result in 
microvascular dysfunction and decline nitric oxide availability.48) In addition, hyperglycemia 
causes up-regulation of the sodium-glucose cotransporter-2 (SGLT-2) leading to increased 
proximal renal sodium absorption, volume expansion, and decreased of diuretics response.49) 
As a result, many previous studies have demonstrated LV diastolic dysfunction and impaired 
LV longitudinal functional reserve in patients with DM.50)51) Furthermore, impaired LV 
longitudinal functional reserve in patients with DM without overt heart disease provided 
incremental prognostic information for composite of death and HF hospitalization.28) 
Recently, as expectations for the effect of SGLT-2 inhibitors on improving HF outcome have 
increased, interests in DM as a risk factor of HFpEF have been amplified. SGLT-2 inhibitors 
have demonstrated convincing reductions in the incidence and risks of HF in patients with 
DM.52-55) Now, studies are underway to prove the beneficial effects of SGLT-2 inhibitors in 
overt HF patients with or without DM.
OBESITY AND OBSTRUCTIVE SLEEP APNEA
Obesity is a major risk factor of HF and also one of the most common comorbidities in 
patients with HFpEF.56) Obesity has several harmful effects in aspects of HF, mediated by 
changes in volume status, cardiac loading, energy substrate utilization, tissue metabolism 
and systemic inflammation that are believed to promote disease progression.57)58) Typically, 
obese patients with HFpEF have increased plasma volume with greater biventricular filling 
pressure, typical myocardial remodeling characterized by increased LV dimensions and 
mass.57)58) Interestingly, obesity is more important risk factor of occurrence of HFpEF in 
women than in men.59) Our previous study also demonstrated overweight women had 
exercise intolerance than lean women through displaying impaired arterial compliance 
during exercise.37) Because obesity is possible to be treated by weight reduction and physical 
activity, many studies have demonstrated significant improvement in cardiac structure 
and function after bariatric surgery, dietary or exercise intervention.60) In obese patients, 
obstructive sleep apnea (OSA) is frequently combined and OSA might deteriorate LV diastolic 
dysfunction and longitudinal systolic function by exposing to episodic hypoxemia, nocturnal 
sympathetic nervous system activation, elevated BP, oxidative stress and inflammation.61)62) 
In our recent randomized, sham controlled clinical trial, continuous positive airway pressure 
treatment for 3 months in patients with severe OSA improved LV diastolic function more than 
sham treatment, and was accompanied by improvements in arterial stiffness and ventricular-
vascular coupling.63) Moreover, we additionally proved that LV mechanical function assessed 
by speckle-tracking echocardiography and right ventricular fractional area change were 
significantly improved by continuous positive airway pressure.64) Hence, obesity and OSA are 
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modifiable risk factors, so it is necessary to actively evaluate and treat them before myocardial 
structural and functional changes are too advanced.
CONCLUSION
HFpEF is a heterogeneous clinical syndrome and the single greatest unmet need in 
cardiovascular medicine. We hope that HFpEF will become a solved disease entity with lots of 
evidence in the future through more scientific phenotype classification in the era of precision 
medicine, improved diagnostic imaging even in early stage of disease, applying appropriate 
drugs and intervention focusing each pathophysiologic mechanism.
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